EANO - EURACAN - SNO Guidelines on circumscribed astrocytic gliomas, glioneuronal, and neuronal tumors

Rudà, Roberta; Capper, David; Waldman, Adam; Pallud, Johan; Minniti, Giuseppe; Kaley, Thomas; Bouffet, Éric; Tabatabai, Ghazaleh; Aronica, Eleonora; Jakola, Asgeir Store; Pfister, Stefan M.; Schiff, David; Lassman, Andrew B.; Solomon, David A.; Soffietti, Riccardo; Weller, Michael; Preusser, Matthias; Idbaïh, Ahmed; Wen, Patrick Y.; Bent, Martin J. van den

doi:10.1093/neuonc/noac188

Cited by 34 publications

(41 citation statements)

References 114 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Thus, we will group the molecular diagnostics of pediatric diffuse low‐grade gliomas and circumscribed astrocytic glioma in this Part 2 review. The specific EANO‐EURACAN‐SNO guideline for molecular workup for circumscribed astrocytic glioma and glioneuronal and neuronal tumors will be discussed in detail in the Part 3 review 3,4 …”

Section: Molecular Diagnosticsmentioning

confidence: 99%

“…and neuronal tumors will be discussed in detail in the Part 3 review. 3,4 Molecular Diagnostics of Pediatric-Type Diffuse High-Grade Gliomas H3 K27M, EZHIP, and EGFR mutation testing should be performed in diffuse gliomas that involve the midline to diagnose diffuse midline glioma, H3 K27-altered. In older adults there is increasing evidence that the midline location of diffuse glioma is also tightly linked with H3 K27M mutation, warranting testing of all patients with midline gliomas regardless of age.…”

Section: Molecular Diagnosticsmentioning

confidence: 99%

See 1 more Smart Citation

The 2021 WHO Classification for Gliomas and Implications on Imaging Diagnosis: Part 2—Summary of Imaging Findings on Pediatric‐Type Diffuse High‐Grade Gliomas, Pediatric‐Type Diffuse Low‐Grade Gliomas, and Circumscribed Astrocytic Gliomas

Park

Vollmuth

Foltyn-Dumitru

et al. 2023

Magnetic Resonance Imaging

View full text Add to dashboard Cite

The fifth edition of the World Health Organization (WHO) classification of central nervous system tumors published in 2021 advances the role of molecular diagnostics in the classification of gliomas by emphasizing integrated diagnoses based on histopathology and molecular information and grouping tumors based on genetic alterations. This Part 2 review focuses on the molecular diagnostics and imaging findings of pediatric-type diffuse high-grade gliomas, pediatric-type diffuse low-grade gliomas, and circumscribed astrocytic gliomas. Each tumor type in pediatric-type diffuse high-grade glioma mostly harbors a distinct molecular marker. On the other hand, in pediatric-type diffuse low-grade gliomas and circumscribed astrocytic gliomas, molecular diagnostics may be extremely complicated at a glance in the 2021 WHO classification. It is crucial for radiologists to understand the molecular diagnostics and imaging findings and leverage the knowledge in clinical practice. Evidence Level: 3 Technical Efficacy: Stage 3.

show abstract

Section: Molecular Diagnosticsmentioning

confidence: 99%

Section: Molecular Diagnosticsmentioning

confidence: 99%

The 2021 WHO Classification for Gliomas and Implications on Imaging Diagnosis: Part 2—Summary of Imaging Findings on Pediatric‐Type Diffuse High‐Grade Gliomas, Pediatric‐Type Diffuse Low‐Grade Gliomas, and Circumscribed Astrocytic Gliomas

Park

Vollmuth

Foltyn-Dumitru

et al. 2023

Magnetic Resonance Imaging

View full text Add to dashboard Cite

show abstract

“…The role of systemic therapy is unclear, and cytotoxic therapies can be considered in cases of progressive or recurrent disease. 54 Prospective evidence on the use of therapies targeting the MAPK pathway in HGAP is lacking.…”

Section: High-grade Astrocytoma With Piloid Featuresmentioning

confidence: 99%

Brain Tumors in Adolescents and Young Adults: A Review

Rousseau,

Bennett,

Lim-Fat

2023

Semin Neurol

View full text Add to dashboard Cite

Brain tumors account for the majority of cancer-related deaths in adolescents and young adults (AYAs), defined as individuals aged 15 to 39. AYAs constitute a distinct population in which both pediatric- and adult-type central nervous system (CNS) tumors can be observed. Clinical manifestations vary depending on tumor location and often include headaches, seizures, focal neurological deficits, and signs of increased intracranial pressure. With the publication of the updated World Health Organization CNS tumor classification in 2021, diagnoses have been redefined to emphasize key molecular alterations. Gliomas represent the majority of malignant brain tumors in this age group. Glioneuronal and neuronal tumors are associated with longstanding refractory epilepsy. The classification of ependymomas and medulloblastomas has been refined, enabling better identification of low-risk tumors that could benefit from treatment de-escalation strategies. Owing to their midline location, germ cell tumors often present with oculomotor and visual alterations as well as endocrinopathies. The management of CNS tumors in AYA is often extrapolated from pediatric and adult guidelines, and generally consists of a combination of surgical resection, radiation therapy, and systemic therapy. Ongoing research is investigating multiple agents targeting molecular alterations, including isocitrate dehydrogenase inhibitors, SHH pathway inhibitors, and BRAF inhibitors. AYA patients with CNS tumors should be managed by multidisciplinary teams and counselled regarding fertility preservation, psychosocial comorbidities, and risks of long-term comorbidities. There is a need for further efforts to design clinical trials targeting CNS tumors in the AYA population.

show abstract

“…23,24 The use of this type of targeted approach is actively being incorporated into the management of PXA. 25 Case 4…”

Section: Casementioning

confidence: 99%

Challenging Cases in Neuro-Oncology

et al. 2022

View full text Add to dashboard Cite

Neuro-oncology encompasses a broad field focusing on an array of neoplasms, many of which can mimic a number of diseases. Neurologists will often be involved in the initial diagnostic evaluation and management of these patients. Their insight is central to optimizing the diagnostic yield and providing high level clinical care. A number of neuro-oncologic cases are reviewed with a goal of increasing the understanding of these diseases in a clinically relevant manner and providing updates on the contemporary thinking in the sub-specialty.

show abstract

EANO - EURACAN - SNO Guidelines on circumscribed astrocytic gliomas, glioneuronal, and neuronal tumors

Cited by 34 publications

References 114 publications

The 2021 WHO Classification for Gliomas and Implications on Imaging Diagnosis: Part 2—Summary of Imaging Findings on Pediatric‐Type Diffuse High‐Grade Gliomas, Pediatric‐Type Diffuse Low‐Grade Gliomas, and Circumscribed Astrocytic Gliomas

The 2021 WHO Classification for Gliomas and Implications on Imaging Diagnosis: Part 2—Summary of Imaging Findings on Pediatric‐Type Diffuse High‐Grade Gliomas, Pediatric‐Type Diffuse Low‐Grade Gliomas, and Circumscribed Astrocytic Gliomas

Brain Tumors in Adolescents and Young Adults: A Review

Challenging Cases in Neuro-Oncology

Contact Info

Product

Resources

About